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Background: The polysaccharides from Liriopes Radix (PSLR) has been indicated to ameliorate insulin signaling
transduction and glucose metabolism. We aimed to investigate whether PSLR exerts an ameliorative effect on renal
damage in diabetes induced by streptozotocin.
Methods: Diabetes was induced with STZ (60 mg/kg) by intraperitoneal injection in rats. Two weeks after STZ
injection, rats in the treatment group were orally dosed with PSLR (200 and 300 mg/kg/day for 8 weeks. The
normal rats were chosen as nondiabetic control group. Changes in renal function-related parameters in plasma and
urine were analyzed at the end of the study. Kidneys were isolated for pathology histology, immunohistochemistry,
and Western blot analyses.
Results: Diabetic rats exhibited renal dysfunction, as evidenced by reduced creatinine clearance, blood urea nitrogen
and proteinuria, along with marked elevation in the ratio of kidney weight to body weight. All of these abnormalities
were significantly reversed by PSLR. The histological examinations revealed amelioration of diabetes-induced glomerular
pathological changes following treatment with PSLR. The less protein expressions of renal nephrin and podocin in
diabetic rats were increased following treatment with PSLR. PSLR reduced the accumulation of ED-1-expressing
macrophages in renal tissue of diabetic rats. PSLR almost completely abolished T cells infiltration and attenuated
the expression of proinflammatory cytokines. PSLR treatments not only reduced the degradation of inhibitory
kappa B kinase, but also downregulated the protein expression of nuclear factor kappa B (NF-κB) and p38
mitogen-activated protein kinase (MAPK) in diabetic kidney.
Conclusions: The results suggest that the renal protective effects of PSLR occur through improved glycemic
control and renal structural changes, which are involved in the inhibition of NF-κB and p-38 MAPK mediated
inflammation.Background
Diabetes mellitus is a metabolic disease usually charac-
terized by the classic triad of polydipsia, polyuria and
polyphagia, consequences of homeostasis disruption
due to impaired glucose metabolism [1]. Diabetic ne-
phropathy (DN), the second most prevalent diabetes-* Correspondence: mcwu@mail.npust.edu.tw; iml@tajen.edu.tw
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unless otherwise stated.associated complication inferior to cardiovascular dis-
orders, impaired the renal function of diabetes patients
and therefore cost appreciable medical labor and re-
source for DN management annually [2]. Although DN
is traditionally considered a non-immune disease, accu-
mulating evidence now indicates that immunologic and
inflammatory mechanisms play significant roles in its
development and progression [3]. It also suggested the
development of DN was associated with the activation
of several signal pathways, including nuclear factor
kappa B (NF-κB) and mitogen-activated protein kinase
(MAPK) [4]. Genetic and pharmacological approachesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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our understanding of the disease pathophysiology, but have
also shown promise as potential therapeutic strategies.
Many herbal extracts or derivatives have been docu-
mented in traditional Chinese medicine (TCM) as hav-
ing clinical effectiveness in treating diabetes mellitus [5].
The tuberous root of Liriope spicata (Liliaceae) were
recorded as Liriopes Radix in the Pharmacopeia of the
People’s Republic of China, are frequently used as
“maidong” in prescriptions for the treatment of diabetes
mellitus. Chemical studies have shown that this plant
mainly includes saponins, polysaccharide and homoisofla-
vonoidal compounds [6]. It has been reported that the
water extract and crude polysaccharides obtained from
Liriopes Radix had considerable hypoglycemic effects [7].
The polysaccharides from Liriopes Radix (PSLR) caused
more marked activation on insulin signaling transduction
in type 2 diabetic mice than the effects produced by water
extract has been also demonstrated [8]. Liriopes Radix is
valued for the ability to promote glucose homeostasis, and
it may therefore be utilized as an adjuvant therapy in the
control of diabetic complications. The potential preventive
effects of PSLR on DN in diabetic rats has been reported
to mediate by down-regulating the system of advanced
glycation end products-receptor for advanced glycation
end products [9]. Actually, anti-inflammatory potential of
Liriopes Radix has been identified [10]. Since the inflam-
matory process is also involved in the pathogenesis of DN,
there is a possibility that PSLR may ameliorate DN by sup-
pression of renal inflammation, but this has never been
explored.
Without intervention, approximately 80% of patients
with type 1 diabetes and 20-40% of those with type 2
diabetes develop overt nephropathy in 10–15 years [11].
The present studies were thus designed to further elu-
cidate whether the renopreventive effects of PSLR be
responsible for the alleviation of diabetic renal inflam-
mation utilizing streptozotocin-induced diabetic rats
(STZ-diabetic rats) as a type-1 diabetic animal model.
Methods
Plant material and extraction
The tuberous root of L. spicata was purchased from a
local market in Pingtung County (Taiwan) on May 2012.
Plant identification was done by Professor Hong T.Y.
(the Department of Biotechnology, Collage of Pharmacy
and Health Care, Tajen University). Random amplified
polymorphic DNA analysis of Liriopes Radix supplied was
also performed to identify DNA polymorphisms. The
voucher specimen (Lot No. LS20120523) has been de-
posited in our laboratory.
Preparation of PSLS was performed according to the
previous study [7]. The powdered material (200 g) was
boiled in distilled water three times (1:4, 1:4, 1:2, w/v),0.5 h each time. Each extract was then filtered and
merged together. Phosphate buffer (pH 5.91) and 0.6 g
of papain (12 u/mg, Biosharp, USA) were added into the
extracts and kept in water-bath (45°C) for 2 h to remove
proteins. After boiled for 5 min, the extracts were stored
overnight at 4°C and filtered next morning. The filtrate
was purified by using the mini pellicon system (ultrafil-
tration membrane Mw cut-off 1000, Millipore, USA)
with 12 l distilled water. The retentate portion was
concentrated and then separated in DEAE-cellulose 52
columns to remove pigments. The water eluted solution
was concentrated and finally lyophilized (Alpha 2–4,
Christ, Germany) and obtained 53.2 g of PSLR from
200 g powdered material. The sugar content of PSLR was
98.1% determined by anthrone-sulfuric acid method at
625 nm using fructose as standard [12].
Animal models
Male Wistar rats (8–10 weeks of age, 200–250 g) were ob-
tained from the Animal Center of National Cheng Kung
University Medical College. To induce diabetes rats were
given a single intravenous injection of 60 mg/kg strep-
tozotocin (STZ; Sigma-Aldrich, Inc., Saint Louis, Missouri,
USA). Animals were considered to be diabetic if they
had plasma glucose concentrations of 350 mg/dl or
greater, in addition to polyuria and other diabetic fea-
tures. All studies were carried out two weeks after the
injection of STZ. All animal procedures were performed
according to the Guidelines for the Care and Use of
Laboratory Animals of the National Institutes of Health
(United States), as well as the guidelines of the Animal
Welfare Act. These studies were conducted with the
approval of the Institutional Animal Care and Use Com-
mittee (IACUC) at Tajen University (approval number:
IACUC 100–29; approval date: December 22, 2011).
Treatment protocols
The selection of dosage regime for the present studies
was according to the previous report that demonstrated
administration with PSLR at 200 and 300 mg/kg for
4 weeks exerted potential effect in improving hyper-
glycemia in diabetic mice [9]. In order to obtain the
significant effect of PSLR on improvement of DN, STZ-
diabetic rats were dosed by oral gavage once per day for
eight weeks with PSLR doses of 200 or 300 mg/kg in a
volume of 1.5 ml/kg distilled water. A vehicle-treated
group of STZ-diabetic rats and normal rats was treated
with 1.5 ml/kg distilled water only over the same treat-
ment period. Animals received standard rat diet (Harlan
Teklad, Madison, WI, USA; Cat. No. 2018) and water ad
libitum throughout the entire treatment period. PSLR
treatment was continued even though the plasma glucose
of STZ-diabetic rats was lower than 350 mg/dl during the
eight-week treatment period. The evening prior to blood
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(given at 18:00), which was consumed immediately, and
thereafter had access to only water. The animals were
transferred to metabolic cages (Shineteh Instruments
Co., Ltd, Taipei, Taiwan) for urine collection 24 hours
before sacrifice. Urine was collected under a layer of
toluene (to inhibit bacteria growth) and stored at 4°C
until analyzed. Toluene used had no detectable effect
on the estimation of albumin and creatinine in the
urines collected in the metabolism experiments.
At the end of the eight-week treatment, rats were
sacrificed using an intraperitoneal injection of sodium
pentobarbital (50 mg/kg). The kidneys were dissected
and rinsed with cold isotonic saline and weighed. An
index of renal hypertrophy was estimated by comparing
the wet weight of the left kidney to total body weight.
The cortical tissues from right kidney were stored imme-
diately at −80°C in liquid nitrogen for biochemical deter-
minations and Western blot analyses. Other kidney
tissues were fixed in 10% neutralized formalin for hist-
ology and immunohistochemistry.
Blood sampling and analysis
Blood sample of rats were centrifuged at 2,000 × g for
10 minutes at 4°C, plasma was removed and aliquot for
the respective analytical determinations. The diagnostic kit
for determinations for plasma levels of glucose (Cat. No.
COD12503) was purchased from BioSystem (Barcelona,
Spain). The plasma creatinine (Cr) concentration was
determined by the commercial assay kit (Cat. No. 221–30)
purchased from Diagnostic Chemicals Limited (Connecti-
cut, USA). Blood urea nitrogen (BUN) was determined
by kinetic reagent (Diagnostic Chemicals Limited, Cat.
No. 283–30). Commercial enzyme-linked immunosorb-
ent assay (ELISA) kits were used quantify glycosylated
hemoglobin (HbA1c) levels (Intergrated Bio Ltd., Taipei,
Taiwan; Cat. No. CSB-E08140r). Kits for determination
of plasma alanine aminotransferase (ALT; EC 2.6.1.2)
(Cat. No. A524-780TM) and aspartate aminotransferase
(AST; EC 2.6.1.1) (Cat. No. A559-780TM) concentra-
tions were purchased from Teco Diagnostics (CA).
Assays were performed according to the manufacturer’s
instructions. All experiments were performed in tripli-
cate to ensure the accuracy of the observations.
Analysis of urine parameters
The 24-h urine collected from each diabetic rat and age-
matched control was centrifuged at 2,000 g for 10 min.
Urinary albumin concentrations were measured by Nephrat
II ELISA kit (Cat. No. NR002) obtained from Exocell, INC.
(PA, PUA). The concentration of Cr in pooled urine
samples was determined by the commercial assay kit
(Diagnostic Chemicals Limited, Cat. No. 221–30). All
analyses were performed in triplicate in accordance withthe manuals provided by the manufacturers. Creatinine
clearance (Ccr) was calculated in individual rats as
follows: Ccr = urine creatinine × urine volume/plasma
creatinine × time [13].
Renal cytokines determination
Renal tissue was homogenized in 10 mmol/L Tris–HCl
buffered solution (pH 7.4) containing 2 mol/l NaCl,
1 mmol/l EDTA, 0.01% Tween 80, 1 mmol/l PMSF, and
centrifuged at 9000 × g for 30 min at 4°C [14]. The re-
sultant supernatant was used for cytokine determination.
The levels of proinflammatory and anti-inflammatory
cytokines were estimated by performing ELISA using
commercial kits. ELISA kits for the determination of
tumor necrosis factor (TNF)α (Cat. No. ab46070), inter-
leukin (IL)-6 (Cat. No. ab100772), and IL-10 (Cat. No.
ab100764) were obtained from Abcam Inc. (Cambridge,
MA, USA). Samples were assayed in triplicate according
to manufacturer’s instructions. The protein concentra-
tions of kidney filtrate were determined according to the
previous method using BSA as a standard [15].
Renal histological analysis
Renal tissues were fixed with 10% neutral formalin phos-
phate buffer, dehydrated through a graded alcohol series
and embedded in paraffin, cut into 4 μm sections and
stained with hematoxylin and eosin (H&E). The sections
were examined with light microscopy by an experienced
pathologist and micrographs from six glomerulums were
obtained randomly with magnification of 400 ×. Mean
glomerular volume was determined from the mean glom-
erular capillary tuft area (AG) by light microscopy of PAS
sections. The areas were determined by light microscopy
and analyzed by dedicated software (Analysis 3.0, Soft
Imaging System, Münster, Germany) as the average area of
50 glomerular profiles (the capillary tuft omitting the prox-
imal tubular tissue and Bowman’s capsule) for each animal.
Glomerular volume (GV) was calculated using the formula
GV= β/k × (AG)
3/2, where GV is glomerular volume, β =
1.38, which is the shape coefficient for spheres (the ideal-
ized shape of glomeruli), k = 1.1, which is a size distribution
coefficient, and AG is the glomerular capillary tuft area
[16]. The index of mesangial expansion was scored by a
quantitative estimate of the mesangial zones width in each
glomerulus, expressed as a function of the total glomerular
area [17]: 0, normal glomeruli; 1, matrix expansion oc-
curred in up to 50% of a glomerulus; 2, matrix expansion
occurred in 50-75% of a glomerulus; 3, matrix expansion
occurred in 75-100% of a glomerulus.
Immunohistochemistry
Formalin-fixed, paraffin-embedded kidney tissue sec-
tions were used for immunohistochemical staining.
After deparaffinization and hydration, the slides were
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HCl, 0.85% NaCl, pH 7.2). Endogenous peroxidase
activity was quenched by incubating with the slides in
methanol and 0.3% H2O2 in methanol. After overnight
incubation with Mouse monoclonal anti-rat monocyte/
macrophage antibody (anti-ED-1) (sc-59103; Santa Cruz
Biotechnology Inc. CA, USA) at 4°C, the slides were
washed in TBS and horseradish peroxidase (HRP)-con-
jugated goat anti-mouse secondary antibody was then
added and the slides were further incubated at room
temperature for 1 h. The slides were washed in TBS and
incubated with diaminobenzidine tetrahydrochloride as
the substrate, and counterstained with hematoxylin. A
negative control without primary antibody was included
in the experiment to verify the antibody specificity.
Intraglomerular ED-1-positive cells were counted in
200 glomeruli/group under 400-fold magnification.
Western blotting
Protein extraction of isolated kidney was performed as
follows [18]. The sample was homogenized in ice-cold
in 1 ml of hypotonic buffer A [10 mmol/l HEPES
(pH 7.8), 10 mmol/l KCl, 2 mmol/l MgCl2, 1 mmol/l
DTT, 0.1 mmol/l EDTA, 0.1 mmol/l phenylmethylsul-
fonylfluoride]. A solution of 80 μl of 10% Nonidet P-40
was added to the homogenates, and the mixture was
centrifuged for 2 min at 14,000 × g. The supernatant
was collected as a cytosolic fraction for the assays of
CD4, CD8, nephrin, podocin, and inhibitory kappa B
kinase (IκB)α. The supernatant containing nuclear pro-
teins was collected for nuclear factor kappa B (NF-κB)
p65, p38 mitogen-activated protein kinase (p38
MAPK), and phospho (p)-p38 MAPK (Thr180/Tyr182).
Before immunoblotting, and the protein concentration
of each tissue was determined using a Bio-Rad protein
assay kit (Bio-Rad Laboratories, Japan) and bovine serum
albumin as a standard, to ensure equal loading among
lanes. Cytosol (70 μg total protein) and nuclear extracts
(50 μg total protein) were separated on a 7.5-15% polyacri-
lamide gel and electophoretically transferred to nitrocellu-
lose membrane. Membranes were blocked with 5% non-
fat dry milk in Tris-buffered saline Tween (20 mmol/l
Tris, pH 7.6, 137 mmol/l NaCl, and 0.1% Tween 20) for
3 h at room temperature, followed by an overnight incuba-
tion at 4°C with with primary antibodies CD4 (Santa Cruz
Biotechnology, Inc., Cat. No. sc-7219), CD8 (Santa Cruz
Biotechnology, Inc., Cat. No. sc-7188), nephrin (Santa
Cruz Biotechnology, Inc., Cat. No. sc-28192), podocin
(Santa Cruz Biotechnology, Inc., Cat. No. sc-21009), NF-
κB p65 (Santa Cruz Biotechnology, Inc., Cat. No. sc-109),
IκBα (Cell Signaling Technology, Beverly, MA, USA; Cat.
No. 9242), p38 MAPK (Cell Signaling Technology; Cat.
No. 9212), p-p38 MAPK (Thr180/Tyr182) (Cell Signaling
Technology; Cat. No. 9211), or β-actin (Santa CruzBiotechnology, Inc.; Cat. No. sc-130656). All antibodies
were used at a dilution of 1:1000. Three times after wash-
ing with Tris-buffered saline Tween 20 (TBST), incubation
with appropriate horseradish peroxidase-conjugated sec-
ondary antibodies were performed for 1 h at room
temperature. After three additional TBST washes, the im-
munoreactive bands were visualized by enhanced chemi-
luminescence (Amersham Biosciences, Buckinghamshire,
UK) according to the manufacturer’s instructions. Band
densities were determined using ATTO Densitograph
Software (ATTO Corporation, Tokyo, Japan) and quanti-
fied as the ratio to β-actin. The mean value for samples
from the vehicle-treated normal rats on each immunoblot,
expressed in densitometry units, was adjusted to a value of
1.0. All experimental sample values were then expressed
relative to this adjusted mean value. Tissue sections were
sampled from 4 independent experiments.
Statistical analysis
The results are presented as the mean ± standard devi-
ation (SD) for each group of animals at the number (n)
indicated. Statistical analysis was performed with one-
way analysis of variance (ANOVA). The Dunnett range
post-hoc comparisons were used to determine the
source of significant differences where appropriate.
The renal morphohistology and the morphologic ana-
lysis for PAS staining were analyzed statistically using
the Kruskal-Wallis Test and Dunn’s Multiple Comparisons
Test. Values of P < 0.05 were considered statistically
significant.
Results
Effects on body weight, fasting blood glucose and
glycosylated hemoglobin contents
During 8-week experiment, STZ-diabetic rats were found
to have significant weight loss when compared with
normal rats (Table 1). The body weight reduction was
not obvious in STZ-diabetic rats receiving PSLR during
the experimental period (Table 1).
Significant increase in fasting blood glucose in STZ-
diabetic was observed when compared to normal control
group and this change was more marked at the 8th week
following diabetes induction. The blood glucose lower-
ing effect was obvious when STZ-diabetic rats were
treated with PSLR at the daily dosage of 200 mg/kg
(20.91 ± 4.12%) and 300 mg/kg (28.37 ± 3.92%) for
8 weeks (Table 1). The value of HbA1c was markedly
higher in STZ-diabetic rats (14.31 ± 1.26%) when com-
pared with theat from normal rats (4.79 ± 1.03%, Table 1).
Treatment PSLR at the daily dosage of 200 and 300 mg/kg
for 8 weeks decreased the levels of HbA1c in STZ-diabetic
rats by 17.88 ± 3.29% and 23.75 ± 2.86% relative to the
value in STZ-diabetic rats that received vehicle, respect-
ively (Table 1).
Table 1 Biochemical parameters and the renal levels of cytokines in experimental animals at the end of the eight-week
treatment
Normal rats STZ-diabetic rats
Vehicle Vehicle PSLR 200 PSLR 300
Body weight (BW) (g/rat) 370.39 ± 13.58d 240.99 ± 16.24b 264.25 ± 15.11b,c 307.72 ± 14.72a,c
Kidney weight (KW) (g) 1.29 ± 0.23c 2.43 ± 0.17a 1.85 ± 0.24a 1.52 ± 0.16
KW/BW ratio × 1000 3.48 ± 0.19d 10.08 ± 0.17b 7.00 ± 0.12b,c 4.94 ± 0.11b,c
Plasma glucose (mg/dl) 92.68 ± 8.59d 425.73 ± 18.07b 336.25 ± 14.92b,c 306.92 ± 15.31b,c
HbAlc (%) 4.79 ± 1.03d 14.31 ± 1.26b 11.75 ± 1.18b 10.91 ± 1.21b
Urine volume (ml/day) 9.26 ± 2.43d 28.16 ± 9.13 b 18.21 ± 6.28b,c 15.84 ± 7.31b,c
Urine protein (mg/day) 6.95 ± 2.84d 34.83 ± 5.29b 16.41 ± 4.13a,c 12.27 ± 5.21d
Plasma Cr (μmol/l) 38.50 ± 6.34d 96.29 ± 8.73b 84.10 ± 8.31b 67.92 ± 7.32b,c
BUN (mmol/l) 7.21 ± 1.58c 16.29 ± 2.80a 13.16 ± 2.11a 11.45 ± 2.21a,c
Ccr (ml/min) 3.88 ± 0.89d 1.65 ± 0.54b 2.37 ± 0.68a,c 2.77 ± 0.34d
Plasma AST (U/l) 125.85 ± 10.47d 374.68 ± 17.34b 219.88 ± 18.26b,c 159.57 ± 17.53d
Plasma ALT (U/l) 57.67 ± 7.92d 218.67 ± 17.12b 145.14 ± 15.78b,c 103.42 ± 13.24a,d
Renal IL-6 (pg/mg protein) 54.06 ± 8.46d 159.34 ± 11.38b 126.34 ± 10.28b,c 105.89 ± 10.94b,c
Renal TNF-α (pg/mg protein) 69.19 ± 9.34d 172.91 ± 10.11b 137.12 ± 9.13b,c 109.45 ± 7.51b,c
Renal IL-10 (pg/mg protein) 64.77 ± 4.17d 28.43 ± 4.25b 36.49 ± 3.91b,c 44.64 ± 3.77b,c
STZ-diabetic rats were dosed by oral gavage once per day for eight weeks with 200 mg/kg/day PSLR (PSLR 200), 300 mg/kg/day PSLR (PSLR 300). Normal or
STZ-diabetic rats receiving vehicle treatment were given the same volume of vehicle (distilled water) used to disperse PSLR. Values (mean ± SD) were obtained for
each group of 8 animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-treated normal rats, respectively. cP < 0.05 and dP < 0.01 compared to the
values of vehicle-treated STZ-diabetic rats, respectively.
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STZ-diabetic rats showed an increase in 24 h urine vol-
ume, accompanied by increase in urine protein excretion
(Table 1). After 8 weeks of 300 mg/kg/day PSLR treat-
ment, 24 h urine volume and 24 h urine protein excre-
tion of STZ-diabetic rats were markedly less than their
vehicle-treated counterparts (Table 1). The levels of Scr
and BUN in STZ-diabetic rats were obviously higher
than normal control group. There was an effective reduc-
tion in the levels of Scr and BUN in STZ-diabetic rats
receiving 8 weeks of PSLR treatment when compared with
their vehicle-counterparts (Table 1). In addition, increased
Ccr in STZ-diabetic rats was observed after 8 weeks of
PSLR treatment (Table 1).
Plasma ALT and AST activities in the diabetic control
group were significantly higher than those in the normal
control group (Table 1). The ALT and AST activities
were markedly reduced in STZ-diabetic rats treated for
eight weeks with PSLR (Table 1).
Influences on the kidney hypertrophy
The mean weight of the left kidney and the ratio of kidney
weight to body weight in vehicle-treated STZ-diabetic rats
were increased significantly compared with those in the
normal group. Treatment of STZ-diabetic rats with
200 mg/kg/day PSLR slightly reduced the degree of
renal hypertrophy (Table 1). Kidney hypertrophy and
the ratio of kidney weight to body weight were markedlyreduced in STZ-diabetic rats treated for eight weeks
with 300 mg/kg/day PSLR (Table 1).
Influences on the renal cytokines
Renal concentrations of inflammatory cytokines TNF-α
and IL-6 of STZ-diabetic rats were significantly higher
compared to their vehicle-treated controls (Table 1).
PSLR treatments reduced renal IL-6 and TNF-α levels in
a dose-dependent manner (Table 1).
The renal IL-10 level of STZ-diabetic rats was signifi-
cantly lower than that in the normal control (Table 1).
The decreased renal IL-10 level in the kidneys of STZ-
diabetic rats was enhanced dose-dependently by PSLR
treatment (Table 1).
Influences on the renal histology
The changes in renal histology of the different groups are
shown in Figure 1A. The sections from the normal control
group were normal sizes without any abnormal phenom-
ena by visual observation (Figure 1A). Conversely, glom-
erular proliferation and mesangial matrix augmentation
occurred in the diabetic group. These broad changes
caused loading of the Bowman’s capsule space and adhe-
sion of capillaries to the wall (Figure 1A). The structures of
the kidney sections of PSLR (300 mg/kg/day)-treated
groups also changed in morphology, however, a decreased
extent of the expansions in the glomerulus and the mesan-
gial matrix were observed (Figure 1A).
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Figure 1 Effects of treatments on the renal histology. (A) Representative photomicrographs (original magnification, 400×) of H&E-stained kidney
sections, (B) glomerular volume, and (C) expansion of matrix index expressed as a quantitative estimate score in experimental groups. STZ-diabetic rats
were dosed by oral gavage once per day for eight weeks with 200 mg/kg PSLR (STZ + PSLR 200) or 300 mg/kg PSLR (STZ + PSLR 300). Normal
or STZ-diabetic rats receiving vehicle treatment were given the same volume of vehicle (distilled water) used to to disperse PSLR. Values (mean ± SD)
were obtained for each group of 4 animals. bP < 0.01 compared to the values of vehicle-treated normal rats (normal + vehicle). cP < 0.05 and dP < 0.01
compared to the values of vehicle-treated STZ-diabetic rats (STZ + vehicle), respectively.
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came readily apparent that a difference in the histo-
logical change was present the diabetic control group
and other groups. The glomerular volume and the ex-
tent of mesangial matrix nearly increased to 2.61- and
2.56-fold in diabetic control group compared with the
normal control group, respectively (Figure 1B and C).
The glomerular volume and the extent of mesangial
matrix in PSLR (300 mg/kg/day)-treated STZ-diabetic
rats were decreased 42.58 ± 5.62 and 41.01 ± 6.25%,
respectively, relative to those in diabetic control group
(Figure 1B and C).
Effects on macrophage infiltration
Kidneys from control rats did not show any significant
macrophage infiltration; however, STZ-diabetic rats
demonstrated prominent macrophage (ED-1-positive cells)
infiltration in the glomerulus (Figure 2). Treatment ofSTZ-diabetic rats with 300 mg/kg/day PSLR for eight
weeks caused a 42.76 ± 6.22% reduction of macrophage
influx relative to that in their vehicle-treated counterparts
(Figure 2).
Effects on renal T cells expression
Renal CD4+ cells protein expression was 3.1-fold higher
in STZ-diabetic rats compared with normal control, and
300 mg/kg/day PSLR treatment attenuated this increase
by 64.28 ± 5.71% (Figure 3A). The STZ-induced upregula-
tion of renal CD8 + T cells was reduced 53.01 ± 5.34% rela-
tive to that in vehicle-treated STZ-diabetic rats after eight
weeks of treatment with 300 mg/kg/day PSLR (Figure 3B).
Changes in protein expressions of nephrin and podocin
Western blot assay indicated that the renal nephrin and
podocin proteins were less expressed in vehicle-treated
STZ-diabetic rats (Figure 4). Eight weeks of PSLR
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crease of renal nephrin and podocin protein expression
in STZ-diabetic rats (Figure 4).
Influences on the renal expression of NF-κB and IκBα
As shown in Figure 5A, the cytosolic IκBα in the kidney
of STZ-diabetic rats was lower than that in the normal
group, and 300 mg/kg/day PSLR treatment reduced IκBα
degradation. The accumulation of NF-κB proteins in the
nucleus of glomeruli from vehicle-treated STZ-diabetic
rats relative to normal group were observed in Figure 5B.
The increased expression of NF-κB protein found in theFigure 2 Effects of treatments on macrophage infiltration. (A) Immuno
renal tissues of STZ-diabetic rats. STZ-diabetic rats were dosed by oral gavage
300 mg/kg PSLR (STZ + PSLR 300). Normal or STZ-diabetic rats receiving vehic
to to disperse PSLR. Arrows indicate ED-1-positive cells. (B) Quantification resu
(mean ± SD) were obtained for each group of 4 animals. bP < 0.01 compared
and dP < 0.01 compared to the values of vehicle-treated STZ-diabetic rats (STZnucleus of kidneys from STZ-diabetic rats was reduced
after 8-week of 300 mg/kg/day PSLR treatment (Figure 5B).
Effects on the protein expression and phosphorylation of
p38 MAPK
The immunoblot results showed that the protein levels
and phosphorylation degree of p38 MAPK were 1.81
and 2.93 fold higher in kidney of STZ-diabetic rats as
compared to the normal group (Figure 6). The STZ also
significantly increased the p-p38 MAPK/p38 MAPK
ratio (by 1.62 fold relative to those in vehicle-treated
normal rats) in kidney of the rats (Figure 6). These STZ-histochemistry staining for macrophage (ED-1-positive cells) in the
once per day for eight weeks with 200 mg/kg PSLR (STZ + PSLR 200) or
le treatment were given the same volume of vehicle (distilled water) used
lts are shown for number of macrophages (ED-1-positive cells). Values
to the values of vehicle-treated normal rats (normal + vehicle). cP < 0.05
+ vehicle), respectively.
Figure 3 Effects of treatments on protein expressions of CD4+ and CD8+ T cells in the renal tissues of STZ-diabetic rats. STZ-diabetic
rats were dosed by oral gavage once per day for eight weeks with 200 mg/kg PSLR (STZ + PSLR 200) or 300 mg/kg PSLR (STZ + PSLR 300). Normal
or STZ-diabetic rats receiving vehicle treatment were given the same volume of vehicle (distilled water) used to to disperse PSLR. Values (mean ± SD)
were obtained for each group of 4 animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-treated normal rats (normal + vehicle),
respectively. cP < 0.05 and dP < 0.01 compared to the values of vehicle-treated STZ-diabetic rats (STZ + vehicle), respectively.
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ation degree of p38 MAPK were reversed in the kidney
after 8-week treatment with 300 mg/kg/day PSLR by
31.05 ± 5.81 and 27.86 ± 6.24% decreases relative to
those in vehicle-treated STZ-diabetic rats (Figure 6).
The ratio of p-p38 MAPK/p38 MAPK were reversed in
the kidney after 8-week treatment with 300 mg/kg/day
PSLR by 43.12 ± 3.25% decreases relative to those in
vehicle-treated STZ-diabetic rats (Figure 6).
Discussion
In the present study, untreated STZ-diabetic rats de-
veloped severe hyperglycemia with polyuria as a result
of osmotic diuresis. It is widely known that hypergly-
cemia can induce microalbuminuria by a hyperfiltra-
tion mechanism [19]. We found that the 8 week PSLR
(300 mg/kg/day) administration regimen significantly
inhibited the glycosylation of hemoglobin by lowering
hyperglycemia in STZ-diabetic rats. The STZ-diabetic
rats treated with PSLR showed an impressive decrease in
the amount of proteinuria in parallel with the decrease in
urinary volume, probably as a result of the amelioration of
hyperglycemia as shown in other studies [7,8].
As the final and major size barrier to the passage of
proteins and other macromolecules, slit diaphragm, the
key structure of foot process, plays a crucial role in the
occurrence and development of proteinuria [20]. Nephrin,
a transmembrane protein belonging to the immunoglobu-
lin superfamily of cell adhesion molecules, was the first
identified structural protein of the podocyte slit diaphragmwhich has dramatic functional importance [21]. Atte-
nuation of nephrin expression in experimental kidney dis-
eases is associated with a loss of the slit diaphragm and
massive proteinuria [21]. Podocin, a stomatin family mem-
ber, is another important component of the glomerular slit
diaphragm complex which colocalizes and interacts with
cytosolic tail of nephrin in the lipid rafts of the podocyte
foot process cell membrane [22]. Mutations in the podo-
cin gene cause severe structural podocyte alterations and
massive proteinuria leading to nephrotic syndrome [22]. It
has been demonstrated that reduction of podocin leads to
decreased expression and obvious redistribution of
nephrin [23]. We thus examined whether antiproteinu-
ric effects of PSLR correlated with alterations in the
abundance of nephrin and podocin. Our observations
demonstrated that rats with diabetes lost their func-
tional podocin, exhibited less nephrin protein expressions,
and developed proteinuria. This down regulated expres-
sion of renal nephrin and podocin protein was alleviated
in the 8 weeks treatment with PSLR. In addition, PSLR
treatment ameliorated proteinuria and glomerular patho-
logical changes in diabetic kidney. We concededly demon-
strated that the renal protective effect of PSLR might be
related with the upregulation on nephrin and podocin ex-
pressions in the glomeruli from diabetic rats.
It is known that among inflammatory cytokines, such
as TNF-α and IL-6 are relevant to the development of
diabetic nephropathy, with diverse actions potentially
involved in the development of complications [24]. Thus,
the suppression on IL-6 and TNF-α could retard or
Figure 4 Effects of treatments on protein expressions of nephrin and podocin in the renal tissues of STZ-diabetic rats. STZ-diabetic rats
were dosed by oral gavage once per day for eight weeks with 200 mg/kg PSLR (STZ + PSLR 200) or 300 mg/kg PSLR (STZ + PSLR 300). Normal or
STZ-diabetic rats receiving vehicle treatment were given the same volume of vehicle (distilled water) used to to disperse PSLR. Values (mean ± SD) were
obtained for each group of 4 animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-treated normal rats (normal + vehicle), respectively.
cP < 0.05 and dP < 0.01 compared to the values of vehicle-treated STZ-diabetic rats (STZ + vehicle), respectively.
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study found that the dietary intake PSLR could effectively
decrease renal IL-6 and TNF-α levels in diabetic rats.
These results similar with the effects of metformin to pro-
tect against DN by modulation of pro-inflammatory gene
expression levels [25]. Antiinflammatory and immunosup-
pressive cytokines such as IL-10, could downregulate the
production of proinflammatory cytokines from monocytesFigure 5 Effects of treatments on protein expressions of renal IκB and
were dosed by oral gavage once per day for eight weeks with 200 mg/kg
STZ-diabetic rats receiving vehicle treatment were given the same volume of
obtained for each group of 4 animals. aP < 0.05 and bP < 0.01 compared to th
cP < 0.05 and dP < 0.01 compared to the values of vehicle-treated STZ-diabetic[26]. The elevation of IL-10 from PSLR supplement as
observed in our present study might contribute to alleviate
renal inflammatory stress. Therefore, our present study
suggested that PSLR could alleviate diabetic renal inflam-
mation via suppressing the release of IL-6 and TNF-α
release, and increasing renal IL-10 levels.
T lymphocytes are known to interact with macro-
phages and regulate the inflammatory cascade [27].NF-κB in the renal tissues of STZ-diabetic rats. STZ-diabetic rats
PSLR (STZ + PSLR 200) or 300 mg/kg PSLR (STZ + PSLR 300). Normal or
vehicle (distilled water) used to to disperse PSLR. Values (mean ± SD) were
e values of vehicle-treated normal rats (normal + vehicle), respectively.
rats (STZ + vehicle), respectively.
Figure 6 Effects of treatments on protein expression and
phosphorylation of p-38 MAPK in the renal tissues of STZ-diabetic
rats. STZ-diabetic rats were dosed by oral gavage once per day for
eight weeks with 200 mg/kg PSLR (STZ + PSLR 200) or 300 mg/kg
PSLR (STZ + PSLR 300). Normal or STZ-diabetic rats receiving vehicle
treatment were given the same volume of vehicle (distilled water)
used to to disperse PSLR. Ratios of p-p38 MAPK/β-actin, p38 MAPK/
β-actin, or p-p38 MAPK/p38 MAPK are expressed as the mean
with SD (n = 4 per group) in each column. aP < 0.05 and bP < 0.01
compared to the values of vehicle-treated normal rats (normal + vehicle),
respectively. cP < 0.05 and dP < 0.01 compared to the values of
vehicle-treated STZ-diabetic rats (STZ + vehicle), respectively.
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activated T lymphocytes, as well as augmented expres-
sion of inflammatory cytokines in the kidneys have been
found in patients with DN [28]. Using accumulation of
ED-1 as a marker of macrophage activation, we have
demonstrated increased activation of macrophage in the
glomeruli of kidney tissue from diabetic animals. The
suppressive effect from PSLR on the expression of ED-1
was observed. Western blot analyses revealed increased
expression of CD4+, CD8 + T cells in diabetic kidneys
were also allivated by PSLR supplement. Therefore, the
possible mechanism of preventing the renal disease pro-
gression may be due to the effect of PSLR on attenuating
inflammation through reducing macrophage and T cells
infiltration in DN.
Studies have also demonstrated that NF-κB was involved
in the induction of monocyte chemotactic protein-1 inmesangial cell cultured under high glucose condition and
subsequently mediated macrophage accumulation [29].
NF-κB is present in the cytoplasma complexed to its
inhibitory protein known as IκB. After activation by a
number of physiological and nonphysiological stimuli,
IκB dissociates from NF-κB within minutes and under-
goes ubiquitination and degradation. Once NF-κB is
released from the inhibitory unit IκB, the NF-κB is then
translocated into the nucleus. Upon its nuclear transloca-
tion, NF-κB undergoes phosphorylation on serine 276 in
its p65 subunit and associates with surrounding chromatin
components. It subsequently binds with DNA and pro-
motes the transcription of proinflammatory cytokines
[30]. After PSLR treatment for 8 weeks, the nucleus
protein levels of NF-κB p65 were significantly inhibited,
implying the effect of PSLR on diabetic rats with renal
injury may result from the inhibition of NF-κB activa-
tion. And in diabetic kidney, the cotosolic protein levels
of IκBα were decreased, while PSLR treatment could
up-regulated IκBα level and decreased the expression of
inflammatory cytokines regulated by NF-κB, such as
TGF-β1, TNF-α and IL-6, which increased in diabetic
rats. Treated rats exhibited reduced levels of glucose
and HbAc1. It should be noted that the significant influ-
ence of PSLR on hyperglycemia in STZ-diabetic rats
was observed, supporting the traditional use of Liriopes
Radix as a hypoglycemic agent [7,8]. We believe that the
ability of PSLR to inactivate hyperglycemia-induced ac-
tivation of NF-κB and thus inhibited the macrophages
infiltration is its likely another mechanisms of action.
Accumulating evidence also suggested the develop-
ment of DN was associated with the activation of several
stress-sensitive signal pathways, including MAPK cas-
cades. p38 MAPK followed by the activation of NF-κB
participates in the intracellular signal transduction and
production of cytokines and chemokines [31]. p38 MAPK
was activated in vivo in glomeruli from diabetic rats and
in vitro in mesangial cells exposed to high glucose [32]. In-
creased renal cortical p38 MAPK activity in diabetic rats
could be attenuated by improved glycemic control [33].
Treatment with PSLR also reduced the elevated levels of
p38 MAPK in the kidneys of STZ-diabetic rats, suggest-
ing that the renal protective effect of PSLR might be
also related with the modulation of p38 MAPK signal
transduction to attenuate diabetes-affected renal dys-
function. We thus concluded that attainment of good
glycemic control by PSLR treatment could abrogate the
increased renal p38 MAPK pathway activation in diabetic
rats and led to minimize risk of DN. This finding may
support the protective role of p38 MAPK and NF-κB
signaling pathways inhibition in the reduction of the de-
velopment of DN. Taken together, all the above results
suggest that the beneficial effect of PSLR in rats with
DN is at least in part through antihyperglycemia which
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tion via reducing NF-κB and p38 MAPK mediated in-
flammatory response. However, further pharmacological
evaluations are required to isolate and identify the active
principles in the plant as well as elucidating their mech-
anisms of action.
Toxicity studies on many herbal preparations have not
been conducted. Although it is generally assumed that
herbal preparations have fewer side effects than modern
medicines; care should be taken with the chronic con-
sumption of large doses of traditional remedies. ALT and
AST are two of the most reliable markers of hepatocellular
injury or necrosis [34]. We found that rats treated with
PSLR exhibited no evidence of hepatotoxicity. Thus, PSLR
could be considered with a margin of safety for oral use.
Since toxicity in humans cannot always be entirely
extrapolated from animal studies, clinical evaluation
should be performed to precisely define the safe dosage
to advice in humans.
Conclusions
These results demonstrate that the renal protective effects
of PSLR occur through improved glycemic control and
renal structural changes, which are involved in the inhib-
ition of NF-κB and p38 MAPK mediated inflammation.
Given these promising preclinical findings, we believe that
PSLR might be considered as potential adjuvant entity for
DN treatment.
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